Spanish dermatology company Almirall (BME: ALM) has announced its annual 2023 financial results.
The Barcelona-based firm revealed revenue for the year of 898.8 million euros ($968.5 million), a 2.3% rise on 2022.
Almirall’s total earnings before interest, taxes, depreciation and amortization (EBITDA) were 174.1 million euros in 2023, a 12.2% decline, mainly due to decreased contributions from other income following milestone collaboration payments that were received last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze